about
KASL clinical practice guidelines: management of chronic hepatitis BThe Clinical Value of Oxymatrine in Preventing Lamivudine Induced YMDD Mutation: A Meta-AnalysisAntiviral Therapy of Liver Cirrhosis Related to Hepatitis B Virus InfectionCurrent and future antiviral drug therapies of hepatitis B chronic infectionTelbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmissionChronic hepatitis B: Advances in treatment.A cutting-edge view on the current state of antiviral drug development.Prospects for inhibiting the post-transcriptional regulation of gene expression in hepatitis B virus.Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strainsResistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates.Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis BEfficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysisComparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B PatientsAdvances in Nucleotide Antiviral Development from Scientific Discovery to Clinical Applications: Tenofovir Disoproxil Fumarate for Hepatitis B.Antiviral therapies: focus on hepatitis B reverse transcriptaseThe efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy.Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection.Continuous long-term entecavir therapy in naïve chronic hepatitis B patients showing partial virologic response.Management of Antiviral Resistance in Chronic Hepatitis B.Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance.Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues.Recent insights into hepatitis B virus-host interactions.Molecular diagnosis and treatment of drug-resistant hepatitis B virus.Management of antiviral drug resistance in chronic hepatitis BTowards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.Antiviral treatment for hepatitis B virus recurrence following liver transplantation.Lamivudine resistance in children with chronic hepatitis B.Pharmacotherapeutic options for hepatitis B.Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators.A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study.Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial.Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype.Long-Term Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleos(t)ide-Experienced Chronic Hepatitis B Patients.Multidrug resistance protein 4 is a critical protein associated with the antiviral efficacy of nucleos(t)ide analogues.Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study.Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.Clinical course of partial virological responders under prolonged entecavir monotherapy in patients with chronic hepatitis B.
P2860
Q26752475-642BEBFE-A05E-47BD-8A74-AB79DF7A1C77Q26778278-814E69BB-5985-4463-B52F-DC7CBE0E0315Q26781962-1CE12A7C-EE99-494F-8E8A-33A2F8FA1559Q28084820-B6E07C70-42C1-4C17-9FC4-3AC20ABB0310Q33560668-3EC43A24-C5E9-4E83-BAA2-63AA3E77583EQ33660010-94E78FB5-D0F5-45B0-968C-85DDAEA941ACQ34036018-8E175F70-C965-4FFA-B4EE-E70A3B046862Q34428554-D1B00A01-7581-4C56-A860-325F0BB3B9D4Q34596639-B8AE1022-51F3-468A-AF15-715FC8B8B948Q34647599-B847BD08-88CB-4034-A523-DE79203088FFQ35105892-9D29D326-83CB-47A8-B9FB-D94A93C98694Q35132805-207C4263-31D7-46A6-B783-A000D8A10380Q35677233-4869AF89-3C0E-40EF-B079-24F57F3DA028Q35906015-78C7A25D-E7A2-4976-8FBA-9D9BF00D34F7Q36467514-252AAFA7-6387-457F-9E33-CBE004E05032Q37097615-7CCB792D-86F1-43C8-8D1C-439F1120D78AQ37335661-47725C53-31B7-40C2-A79A-388C93C7C108Q37359386-FE2E5F55-ACE1-4E4F-AF9B-605505B46335Q37696029-411AFFA6-6ECB-4F13-8DDF-83AA7704970DQ37738814-6E4001EE-D98F-4A14-97FB-CAC578FFB089Q38071396-86B473EE-DA7A-40BA-8CE5-81002DA4F164Q38074646-B2437E66-5EC2-49D9-8D02-225409D2C261Q38194061-B9CD2AC7-D389-473B-8B13-E38542503EAFQ38219020-DC0644C4-16D3-48FC-A721-777A60A0556EQ38247981-16508374-1B25-4546-9B8F-8D5027646350Q38351585-B3FC7F2A-729A-4C70-B816-642A38BF077EQ38446412-CED32D3F-F6BA-479E-B760-C9EE396AFF33Q38456918-716F1D3C-E713-4BDD-AECD-98FC3568300DQ38631076-554A7847-D55E-4771-B658-B7E825D6F2DBQ38770516-1FF986F8-E5C4-4443-ACAC-4A303A6501FCQ38782392-DFA2EBF7-98F8-4D84-9554-CF16AA7A0032Q40261148-22A3DB3A-9020-4AAA-88DD-6E76BBCD2599Q40665887-D1AEEE97-E328-4C08-BFA7-3B3251EAEDB6Q40707320-5BCAA1B1-4901-4599-8224-CD87E5272797Q40749549-7ED16852-3131-4313-BE98-583E29ADFC21Q40771426-E794B58E-6284-4060-A42F-424346E13AF2Q40967783-F8C2066F-5BF5-462A-891D-37B05047CC5FQ41175515-19BBA107-06A1-4798-BE2F-9031F8CA4B55Q41538789-3C8F2299-65B8-485C-BBFC-613AC0B8481EQ41583273-CADCA1B5-0D64-4CC0-99FF-5A6E7C4B1EE3
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Management of treatment failure in chronic hepatitis B.
@en
Management of treatment failure in chronic hepatitis B.
@nl
type
label
Management of treatment failure in chronic hepatitis B.
@en
Management of treatment failure in chronic hepatitis B.
@nl
prefLabel
Management of treatment failure in chronic hepatitis B.
@en
Management of treatment failure in chronic hepatitis B.
@nl
P1476
Management of treatment failure in chronic hepatitis B
@en
P2093
Stephen Locarnini
P304
P356
10.1016/S0168-8278(12)60012-9
P478
56 Suppl 1
P577
2012-01-01T00:00:00Z